One autoantibody is not one risk: stimulated testing splits the group

Design

prospective natural-history cohort analysis; Cox proportional hazards and random forest models, age-stratified

Population

first- and second-degree relatives of people with type 1 diabetes, confirmed positive for a single islet autoantibody, in TrialNet Pathway to Prevention

Primary outcome

time to multiple autoantibody positivity or stage 3 type 1 diabetes

Effect

combined OGTT-stimulated glucose and C-peptide measures identified subsets with more than 50% progression at 2 years and groups with under 10% at 5 years

Among first- and second-degree relatives in the TrialNet Pathway to Prevention study who screened positive for a single islet autoantibody, Cox models and random forest analyses tested which metabolic measures predicted progression to multiple autoantibody positivity or stage 3 type 1 diabetes. Measures combining oral glucose tolerance test-stimulated glucose with C-peptide — that is, indices of beta-cell dysfunction rather than glucose or C-peptide alone — were associated with progression consistently across age bands (0-8, 8-16 and 16 years and over) and across antibody types.

The separation achieved is what makes this usable. Data-driven cutoffs picked out small subsets with more than 50% progression at two years, and large groups with under 10% at five years. Isolated glucose, isolated C-peptide, insulin resistance indices and the traditional risk factors all behaved inconsistently, varying by age and by which antibody was present.

Single-autoantibody positivity has been the awkward middle ground of screening: too much risk to discharge, too little to monitor intensively, and no way to tell the two apart. A stimulated test at the point of confirmation would let most of these families step down to light surveillance and direct the intensive monitoring — and any future disease-modifying therapy — at the few who need it.

• Confirm a single positive autoantibody before acting on it; transient positivity is common
• Where a stimulated test is available, use combined glucose-and-C-peptide indices, not fasting glucose alone
• Interpret risk alongside age and which antibody is present — the two modify each other
• Teach the family to recognise stage 3 presentation regardless of the risk estimate
• In Indian practice, access to formal OGTT-based beta-cell testing outside research settings remains limited — say so rather than implying the test is routinely available

Why it matters

It gives the awkward single-antibody-positive family something better than an open-ended 'we will keep watching'.

Don't overread it

This is a prospective natural-history cohort, not a trial — it identifies who progresses, not who benefits from intervening.

The statistics, in plain English

These are observational associations within a screened cohort, so the cutoffs describe risk rather than cause it. Data-driven cutoffs derived and tested in the same dataset tend to look better there than they will elsewhere; the more than 50% two-year and under 10% five-year figures are best read as the achievable separation, not as calibrated numbers to quote to a family.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.